Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Collaboration with Susan G. Komen and the NeoBIG program

IMPAKT

26 - 28 Jun 2009

Published: 19 Sep 2009

Views: 12454

Rating:

Save

Prof Martine Piccart - President of EORTC and Chair of BIG

Prof Martine Piccart, President of EORTC, Chair of BIG and future president of ESMO, discusses the NeoBIG program and collaboration with both Susan G. Komen for the Cure and ESMO. Speaking at IMPAKT 2009.

Categories:
Breast
Biomarkers

Related Videos

SABCS 2023: Latest breast cancer diagnostics guidelines

Prof Nadia Harbeck and Prof Giuseppe Curigliano

SABCS 2023: Latest breast cancer diagnostics guidelines ( Prof Nadia Harbeck and Prof Giuseppe Curigliano )

Dr Nita Nair - Apollo Cancer Centres, Mumbai

Breast Cancer ( Dr Nita Nair - Apollo Cancer Centres, Mumbai )

Genomic testing: Awareness and effective communication between healthcare...

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

Early-stage breast cancer detection in breast milk

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain

Early-stage breast cancer detection in breast milk ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Advancing breast cancer treatment in Uganda by improving molecular testing

Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda

Advancing breast cancer treatment in Uganda by improving molecular testing ( Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda )

Somatic mutation profile of breast cancer in Uganda

Dr Manoj Menon - Fred Hutchinson Cancer Center, Seattle, USA

CDK4/6 inhibitors added to first line show no greater benefit when compared to...

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )

More from ecancer